Stem cells-derived natural killer cells for cancer immunotherapy: current protocols, feasibility, and benefits of ex vivo generated natural killer cells in treatment of advanced solid tumors Hamid KhodayariSaeed KhodayariKarim Nayernia Review 04 July 2021 Pages: 3369 - 3395
Intersection of FcγRIIB, the microbiome, and checkpoint inhibitors in antitumor immunity Kirsten M. BaecherMandy L. Ford Review 09 July 2021 Pages: 3397 - 3404
Combined vaccine-immune-checkpoint inhibition constitutes a promising strategy for treatment of dMMR tumors Inken SalewskiSteffen KuntoffClaudia Maletzki Original Article Open access 18 April 2021 Pages: 3405 - 3419
Interruption of MDM2 signaling augments MDM2-targeted T cell-based antitumor immunotherapy through antigen-presenting machinery Michihisa KonoTakumi KumaiYasuaki Harabuchi Original Article 18 April 2021 Pages: 3421 - 3434
Nutrient supplements from selected botanicals mediated immune modulation of the tumor microenvironment and antitumor mechanism Hui-Ming ChenLinus SunShu-Hsia Chen Original Article 20 April 2021 Pages: 3435 - 3449
A prime/boost vaccine platform efficiently identifies CD27 agonism and depletion of myeloid-derived suppressor cells as therapies that rationally combine with checkpoint blockade in ovarian cancer A. J. R. McGrayC. EppolitoK. Odunsi Original Article 20 April 2021 Pages: 3451 - 3460
Exhaustion in tumor-infiltrating Mucosal-Associated Invariant T (MAIT) cells from colon cancer patients William RodinPatrik SundströmMarianne Quiding Järbrink Original Article Open access 22 April 2021 Pages: 3461 - 3475
Megakaryoblastic leukemia: a study on novel role of clinically significant long non-coding RNA signatures in megakaryocyte development during treatment with phorbol ester Swati DahariyaSanjeev RaghuwanshiRavi Kumar Gutti Original Article 23 April 2021 Pages: 3477 - 3488
Human leukocyte antigen I is significantly downregulated in patients with myxoid liposarcomas Naoki OikeHiroyuki KawashimaNaoto Endo Original Article Open access 24 April 2021 Pages: 3489 - 3499
CD19 CAR-T cell treatment conferred sustained remission in B-ALL patients with minimal residual disease Wenyi LuYunxiong WeiMingfeng Zhao Original Article Open access 25 April 2021 Pages: 3501 - 3511
Blood tumor mutation burden can predict the clinical response to immune checkpoint inhibitors in advanced non-small cell lung cancer patients Xi ChenLiangjie FangJianying Zhou Original Article 25 April 2021 Pages: 3513 - 3524
COM902, a novel therapeutic antibody targeting TIGIT augments anti-tumor T cell function in combination with PVRIG or PD-1 pathway blockade Kyle HansenSandeep KumarMaya F. Kotturi Original Article 26 April 2021 Pages: 3525 - 3540
Enhanced anti-melanoma efficacy through a combination of the armed oncolytic adenovirus ZD55-IL-24 and immune checkpoint blockade in B16-bearing immunocompetent mouse model Hai-Jun HuXiu LiangXin-Yuan Liu Original Article Open access 26 April 2021 Pages: 3541 - 3555
IL-7 coupled with IL-12 increases intratumoral T cell clonality, leading to complete regression of non-immunogenic tumors Mamoru TasakiMidori YamashitaShinsuke Nakao Original Article Open access 28 April 2021 Pages: 3557 - 3571
Immune infiltrate diversity confers a good prognosis in follicular lymphoma Anna-Maria TsakiroglouSusan AstleyKim Linton Original Article Open access 30 April 2021 Pages: 3573 - 3585
A novel immune-related gene-based prognostic signature to predict biochemical recurrence in patients with prostate cancer after radical prostatectomy Daojun LvXiangkun WuGuohua Zeng Original Article 02 May 2021 Pages: 3587 - 3602
CD38 identifies pre-activated CD8+ T cells which can be reinvigorated by anti-PD-1 blockade in human lung cancer Pin WuLufeng ZhaoYing Chai Original Article Open access 02 May 2021 Pages: 3603 - 3616
Human hydatid cyst fluid-induced therapeutic anti-cancer immune responses via NK1.1+ cell activation in mice Edgardo BerrielTeresa FreireEduardo Osinaga Original Article 04 May 2021 Pages: 3617 - 3627
The human anti-CD40 agonist antibody mitazalimab (ADC-1013; JNJ-64457107) activates antigen-presenting cells, improves expansion of antigen-specific T cells, and enhances anti-tumor efficacy of a model cancer vaccine in vivo Adnan DeronicAnneli NilssonPeter Ellmark Original Article Open access 05 May 2021 Pages: 3629 - 3642
Circulating PD-L1 levels change during bevacizumab-based treatment in recurrent glioma Maximilian J. MairAyseguel Ilhan-MutluAnna S. Berghoff Original Article Open access 06 May 2021 Pages: 3643 - 3650
Comprehensive analysis of a chemokine- and chemokine receptor family-based signature for patients with lung adenocarcinoma Tao FanYu LiuJie He Original Article 11 May 2021 Pages: 3651 - 3667
Mechanistic insights into immune checkpoint inhibitor-related hypophysitis: a form of paraneoplastic syndrome Keitaro KanieGenzo IguchiYutaka Takahashi Original Article Open access 11 May 2021 Pages: 3669 - 3677
Telomerase-based GX301 cancer vaccine in patients with metastatic castration-resistant prostate cancer: a randomized phase II trial Gilberto FilaciDaniela FenoglioFrancesco Boccardo Clinical Trial Report Open access 05 August 2021 Pages: 3679 - 3692
The PI3Kδ inhibitor idelalisib impairs the function of human dendritic cells Christiane BraunSebastian SchlaweckAnnkristin Heine Research Report Open access 25 June 2021 Pages: 3693 - 3700
CD16xCD33 Bispecific Killer Cell Engager (BiKE) as potential immunotherapeutic in pediatric patients with AML and biphenotypic ALL Sarah B. ReusingDan A. ValleraFlorian Babor Research Report Open access 16 August 2021 Pages: 3701 - 3708
Correction to: CD16xCD33 Bispecific Killer Cell Engager (BiKE) as potential immunotherapeutic in pediatric patients with AML and biphenotypic ALL Sarah B. ReusingDan A. ValleraFlorian Babor Correction Open access 07 September 2021 Pages: 3709 - 3709
